Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Formosan Medical Association = Taiwan yi zhi"
DOI: 10.1016/j.jfma.2019.10.003
Abstract: BACKGROUND Mongolia has the highest prevalence of hepatitis C virus (HCV) infection worldwide. Ledipasvir/sofosbuvir (LDV/SOF) was introduced to Mongolia since 2016 for HCV eradication. It has been reported that HCV resistance-associated substitutions (RASs) would affect… read more here.
Keywords: ldv sof; hepatitis; treatment; ldv ... See more keywords